Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101
Of the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase…
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)
Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial…
Sangfor Receives Frost & Sullivan’s 2025 APAC Customer Value Leadership Recognition in the Extended Detection and Response Market
Frost & Sullivan applauds Sangfor for delivering advanced, AI-powered cybersecurity with exceptional…
Quantum Metal Recovery Inc. Responds to Besra Gold’s ASX Announcement, Initiates Legal Proceedings in Ontario
PENANG, Malaysia, June 6, 2025 /PRNewswire/ -- Quantum Metal Recovery Inc. (QMRI),…
FutureCeuticals, Inc. Announces Peer-Reviewed Publication Highlighting Cellular Health and Immune Support Benefits of vitAlign
MOMENCE, Ill., June 5, 2025 /PRNewswire/ -- New research published in the International Journal…
